Affiliation: Yale University
- Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistanceMax Lataillade
Yale University School of Medicine, New Haven, CT, USA
Antivir Ther 12:563-70. 2007....
- A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study resultsMichael J Kozal
Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut, USA
HIV Clin Trials 13:119-30. 2012..The reference regimen consisted of ATV 300 mg/RTV 100 mg qd + tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg qd (ATV/r+TDF/FTC)...
- Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participantsShaili Gupta
Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA
J Int Assoc Physicians AIDS Care (Chic) 8:87-92. 2009..All patients tolerated this regimen over a course of 25 to 82 weeks, and had good virologic and immunologic outcome with a decrease in HIV RNA levels to <50 copies/mL and a mean CD4 count increase of 234 cells/mm(3)...
- Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levelsMichael J Kozal
Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA
Antivir Ther 16:925-9. 2011..The objectives of this study were to determine the prevalence of low-level K65R variants within different HIV-1 subtypes and to assess the effects of antiretroviral exposure on K65R variant levels...
- The hunt for HIV-1 integrase inhibitorsMax Lataillade
Division of Infectious Diseases, Yale University School of Medicine, LLCI 100D, 300 Cedar Street, Suite 169, New Haven, Connecticut 06520, USA
AIDS Patient Care STDS 20:489-501. 2006..Furthermore, we review the different INIs under development, their mechanism of actions, site of IN inhibition, potency, resistance patterns, and discuss the early clinical trial results...